secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2024-05-30T23:59:59+00:00
Accession:  0001193125-24-150395
Event type: other
Sentiment:  neutral
Materiality: 0.30
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Spyre Therapeutics updates share count: 50.8M actual, 65.3M pro forma
---------------------------------------------------------------------

- As of May 29, 2024, common shares outstanding: 50,782,384.
- Pro forma shares (incl. Series A & B preferred conversion): ~65.3 million.
- Conversion of Series B Preferred was effective per prior 8-K filed May 15, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000119312524150395/0001193125-24-150395-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000119312524150395/d806070d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-150395

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer